Vaccine ETF Cathay (159643) closes up more than 1.4%, signaling a potential turning point for medical and healthcare demand

Ask AI: How will the innovative drug market perform in April to May?

On March 30, the Cathay Vaccine ETF (159643) rose by more than 1.4%, and pharmaceutical domestic demand may be approaching a turning point.

Huafu Securities noted that, considering catalysts from upcoming conferences such as AACR and ASCO, as well as the high-growth performance on the revenue side of innovative drug companies, the innovative drug market will see fundamentals and sentiment reinforcing each other. April to May will be a period when innovative drugs may deliver clearly higher-than-benchmark returns. In the medium to long term, the technology innovation theme is regarded as the most explicit main line for the pharmaceutical sector in 2026. Specific strategies include: for innovative drugs, focusing on companies with revenue and earnings that are being realized, targets with data or BD outcomes that exceed expectations, and cutting-edge technology platforms; for medical devices, equipment should benefit from replenishment cycles and procurement and tendering, while consumables should benefit from innovation consumables that gain from centralized procurement. In addition, given that the Central Economic Work Conference explicitly mentioned that in 2026 China will adhere to domestic demand as the guiding force and build a strong domestic market, pharmaceutical domestic-demand-related companies may also see a turning point.

The Cathay Vaccine ETF (159643) tracks the Vaccine Biotech Index (980015). This index selects securities of listed companies involved in businesses such as biologics and medical research and development from the market as index constituents, to reflect the overall performance of listed company securities in the vaccine and related biotech industries. The index reflects the overall performance of enterprises in the biopharmaceutical field, especially those with strong competitive advantages in vaccine development and production. In terms of style, it leans toward growth-oriented investing.

Risk disclosure: Mention of individual stocks is only for industry event analysis and does not constitute any recommendation or investment advice for any specific stock. Short-term gains and losses of indices are for reference only and do not represent future performance, nor do they constitute any commitment or guarantee regarding fund performance. Views may be adjusted according to changes in market conditions and do not constitute investment advice or commitments. Different funds have different risk-return characteristics. Investors are kindly reminded to carefully read the fund legal documents, fully understand product features, risk levels, and profit distribution principles, choose products that match their own risk tolerance, and invest prudently. For fund fees and rates, please refer to the legal documents.

The Daily Economic News